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OBJECTIVE: To report on the trends in new and recur-
rent tuberculosis (TB) case notifi  cations in a rural dis-
trict of Malawi that has embarked on large-scale roll-
out of antiretroviral treatment (ART). 
METHODS: Descriptive study analysing TB case notifi  -
cation and ART enrolment data between 2002 and 2009.
RESULTS:  There were a total of 10 070 new and 755 re-
current TB cases. ART scale-up started in 2003, and by 
2007 an estimated 80% ART coverage had been achieved 
and was sustained thereafter. For new TB cases, an ini-
tial increase in case notifi  cations in the fi  rst years after 
starting ART (2002–2005) was followed by a highly sig-
nifi  cant and sustained decline from 259 to 173 TB cases 
per 100  000 population (χ2 for trend 261, P < 0.001, 
cumulative reduction for 2005–2009 = 33%, 95%CI 
27–39). For recurrent TB, the initial increase was fol-
lowed by a signifi  cant drop, from 20 to 15 cases/100 000 
(χ2 for linear trend = 8.3, P = 0.004, constituting a 
25% (95%CI 9–49) cumulative reduction between 2006 
and 2009. From 2005 to 2009, ART averted an esti-
mated 1164 (95%CI 847–1480) new TB cases and 78 
(95%CI 23–151) recurrent TB cases. 
CONCLUSIONS:  High ART implementation coverage is 
associated with a very signifi  cant declining trend in new 
and recurrent TB case notifi  cations at population level. 
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HUMAN IMMUNODEFICIENCY virus (HIV) pro-
motes progression to active tuberculosis (TB) disease 
in both recently acquired and latent Mycobacterium 
tuberculosis infection.1–3 HIV is the most powerful 
known risk factor for reactivation of latent M. tuber-
culosis, with up to 10% of infected individuals at risk 
of developing TB per year.4 HIV is also known to in-
crease the rates of recurrent TB disease after success-
ful completion of treatment for a fi  rst episode.4–6 As a 
result of the impact of HIV, countries with high HIV 
prevalence have had a two- to fi  ve-fold increase in 
annual TB case notifi  cation rates over the last de-
cade.4,7 This increase in TB burden has adversely af-
fected TB programmes and has strained available hu-
man and fi  nancial resources at programme level.4,8 
Observational cohort studies in a wide range of 
settings have demonstrated that antiretroviral treat-
ment (ART), through immune reconstitution, is asso-
ciated with a 54% to 92% reduction in TB incidence 
at the individual patient level and a halving of the 
risk of TB recurrence.7,9–13 It logically follows that if 
a large proportion of HIV-positive individuals in high 
HIV prevalence settings are offered ART, the reduc-
tion in TB incidence at the individual patient level 
should also have a benefi  cial impact on TB incidence 
and case notifi  cation at the population level. How-
ever, empirical data on the impact of ART on TB case 
notifi  cation at the community level are lacking.7 
Thyolo District in rural southern Malawi had a 
global and adult HIV prevalence of respectively 10% 
and 21% in 2007.14 The district has been progressively 
scaling up HIV/AIDS (acquired immune-defi  ciency 
syndrome) care and ART since 2003. The district 
achieved and sustained universal ART access from 
2007 onwards (sustained access for at least 80% of 
those in need).15,16 We hypothesised that such a large 
scale-up and coverage of ART at the population level 
might have been associated with a decrease in dis-
trict TB case notifi  cations. We thus report on trends 
in new and recurrent TB case notifi  cations at the 
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district level for the period 2002–2009 in relation to 
ART scale-up. 
METHODS
Study setting and population 
This retrospective cross-sectional descriptive study 
was conducted in Thyolo District, one of the most 
populated rural districts in Malawi. All consecutively 
registered new and recurrent cases of TB for the pe-
riod 2002–2009 were included in the analysis. Since 
1997, Médecins Sans Frontières (MSF) has been 
working in close collaboration with the district health 
services of the Malawi Ministry of Health (MoH) in 
setting out a comprehensive HIV/AIDS prevention and 
care programme. Chronologically, the project evolved 
as follows: voluntary counselling, HIV testing and 
home-based care from January 1998; HIV testing for 
all TB patients, including cotrimoxazole prophylaxis 
and management of opportunistic infections, from 
June 1999;17 prevention of mother-to-child transmis-
sion18 and HIV/AIDS consultations at hospital and 
health centres from 2002; ART initiation at the dis-
trict hospital in late 2003, which was progressively 
scaled up to include health centres; and universal 
ART access (at least 80% coverage of those in need) 
achieved in 2007 and sustained thereafter. Manage-
ment and reporting of TB and HIV/AIDS activities, 
including ART, are in line with Malawi MoH and 
World Health Organization (WHO) guidelines.19,20 All 
HIV-positive patients assessed as being WHO Clinical 
Stage 3 or 4, or with a CD4 count of <250 cells/mm3 
(irrespective of WHO staging), are considered eligible 
for ART. HIV/AIDS care, ART and TB treatment are 
provided free of charge. 
For the purposes of this study, new TB cases in-
clude individuals starting TB treatment for the fi  rst 
time with pulmonary (smear-positive or -negative) or 
extra-pulmonary TB (EPTB); recurrent TB includes 
relapse cases and the ‘other’ category. 
Data collection and statistical analysis 
Cumulative data on annual TB case notifi  cations 
were obtained from the district TB register for the pe-
riod 2002–2009. TB case notifi  cation was standard-
ised per 100  000 population per year. Yearly district 
population data were based on national demographic 
health surveys (DHS) and census data.21 The total 
numbers of individuals ever enrolled in HIV/AIDS care 
and ART on an annual basis were derived from the 
FUCHIA database (Follow-Up and Care of HIV In-
fection and AIDS [FUCHIA], Epicentre, Paris, France) 
and the routine district reporting system.
The χ2 test for trend was used to test for linear 
trends. The level of signifi  cance was set at P ⩽ 0.05, 
and 95% confi   dence intervals (CIs) were used 
throughout. Data were analysed using Microsoft 
Excel (Microsoft, Redmonds, WA, USA) and STATA 
8.0 software (Stata Corporation, College Station, 
TX, USA). 
Ethics clearance
The TB and ART programmes in Thyolo are imple-
mented in close collaboration with the MoH of Ma-
lawi, in line with existing national guidelines. The 
study received ethics clearance from the ethics review 
boards of MSF and the International Union Against 
Tuberculosis and Lung Disease.
RESULTS
Characteristics of the study population
Over the study period (2002–2009) there were a to-
tal of 10  070 newly registered TB cases, comprising 
4116 cases of smear-positive pulmonary TB (PTB), 
3445 cases of smear-negative PTB and 2509 cases of 
EPTB. A total of 755 cases of recurrent TB were also 
reported, including 406 relapses and 349 in the ‘other’ 
category (Table 1).
Trend in TB case notiﬁ  cation and relation 
to enrolment in HIV/AIDS care and ART
Table 2 shows (by year) the population of Thyolo, 
numbers of HIV-infected persons started on ART and 
case notifi  cations for new and recurrent TB in Thyolo 
District, Malawi. The Figure shows the trend in TB 
case rates (new cases and recurrent TB cases) in rela-
tion to ART scale-up. In terms of ART scale-up 
(started in 2003), by the end of 2006 an estimated 
57 438 of the 574 384 inhabitants in the district were 
HIV-positive (10% global HIV prevalence); of these, 
an estimated 11  487 (20%) were in urgent need of 
ART, including 6216 who were placed on ART by 
the end of 2006, constituting about 54% of the total 
population in need of ART at the time. Universal ac-
cess (at least 80% ART coverage for those in need) 
was achieved in 2007 and sustained thereafter. 
For new cases of TB, there was an initial increase 
in case notifi  cations in the fi  rst years after starting 
Table 1  Annual case reporting for new and recurrent TB 
for the period 2002–2009, Thyolo District, Malawi 
Year
New TB cases 
Recurrent TB Smear-
positive
PTB
Smear-
negative
PTB EPTB Total Relapse Other Total
2002  459  352  309  1  120  37   0  37 
2003  464  315  282  1  061  49  33  82 
2004  591  428  346  1  365  58  40  98
2005  580  500  365  1  445  73  60 113
2006  554  608  308  1  470  63  53 116
2007  545  497  306  1  348  48  56 104
2008  471  387  313  1  171  40  48  88
2009  452  358  280  1  090  38  59  97
 Total 4116 3445 2509 10  070 406 349 755
TB = tuberculosis; PTB = pulmonary TB; EPTB = extra-pulmonary TB.Declining   TB   case   rates   with   ART  935
ART (2002–2005). However, from 2005 onwards 
(2005 was the peak for TB case notifi  cations), there 
was a highly signifi  cant and sustained decrease in case 
notifi  cations, from 259 to 173 cases/100  000 (χ2 for 
linear trend 261, P < 0.001), accounting for a 33% 
(95%CI 27–39) reduction in case rates over a 5-year 
period (2005–2009). The mean incremental reduc-
tion in case rates for new TB from 2005 onwards was 
17/100 000/year.
For recurrent cases of TB, there was also an initial 
increase, followed by a signifi  cant decrease from 2006 
onwards, from 20 to 15 cases/100  000 (χ2 for linear 
trend = 8.3, P = 0.004), constituting a 25% reduc-
tion (95%CI 9–49). The mean incremental reduction 
in case rates for recurrent TB from 2006 onwards 
was one case/100 000/year.
If ART scale-up was causally related to the decline 
in TB case notifi  cation rates, ART averted an esti-
mated 1164 (95%CI 847–1480) new cases of TB and 
78 (95%CI 23–151) recurrent TB cases from 2005 to 
2009 (Table 3). 
DISCUSSION
In a rural district of Malawi that has embarked on 
scaling up ART, there appears to be a highly signifi  -
cant declining trend in TB case notifi  cation. This is 
also one of the fi  rst reports using routinely collected 
data showing the benefi  cial impact of high ART cov-
erage on TB case notifi  cation at the community level. 
The benefi  t is apparent for both new and recurrent 
cases of TB.
A number of observations merit discussion. First, 
an initial increase in TB case notifi  cation in the early 
years of initiating ART is followed by a decline. Al-
though we cannot be certain, the initial increase may 
be related to better TB case detection through scale-
up of ART services:22 TB suspects being enrolled into 
HIV care and not dying before their TB manifests, 
immune reconstitution unmasking TB in patients on 
ART,23 or a rise in TB incidence due to low propor-
tions of the HIV-positive (susceptible) population re-
ceiving ART. The comprehensive support activities 
provided by MSF in the district from 1999 onwards, 
particularly in providing new TB infrastructure, hu-
man resources and consumables for the district labo-
ratory, drug support to all peripheral health facilities, 
HIV testing, cotrimoxazole prophylaxis and manage-
ment of opportunistic infections,17 are all likely to 
Table 2  Population estimates, numbers of HIV-infected persons started on antiretroviral treatment and case notiﬁ  cations 
for new and recurrent TB in Thyolo District, Malawi, 2002–2009
Year
Total population 
Thyolo District 
n
Patients ever
enrolled in 
HIV/AIDS care 
n
Patients ever 
started on ART
n
New TB cases Recurrent TB cases
Total
n
Case rate
/100 000 (95%CI)
Total
n
Case rate
/100 000 (95%CI)
2002 507  426  2  711       0 1120 220  (208–234)  37  7  (5–10)
2003 523  162  4  383     424 1061 203  (191–215)  82  16  (12–19)
2004 539 610   6 609   1 550 1365 253 (240–268)   98 18 (15–22)
2005 556 700   8 765   3 145 1445 259 (246–273) 113 20 (17–24)
2006 574 384 11 622   6 216 1470 255 (243–269) 116 20 (17–24)
2007 592 630 14 627 11 525 1348 227 (215–239) 104 18 (14–21)
2008 611 424 18 437 16 106 1171 191 (180–203)   88 14 (12–18)
2009 630 756 23 395 21 064 1090 173 (162–183)   97 15 (12–18)
HIV = human immunodeﬁ  ciency virus; TB = tuberculosis; AIDS = acquired immune-deﬁ  ciency syndrome; ART = antiretroviral treatment; 
CI = conﬁ  dence interval.
Figure  A. Trend in notiﬁ  cation of new cases of TB (A) and 
cases of recurrent TB (B) in relation to the scale-up of ART, Thyolo 
District, Malawi, 2002–2009. TB = tuberculosis; ART = antiretro-
viral treatment. This image can be viewed online in colour at 
http://www.ingentaconnect.com/content/iuatld/ijtld/2011/ 
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have brought more ill patients into the health system 
and contributed to improved referrals and diagnosis 
of TB suspects. Furthermore, support for community 
TB-HIV-related activities, including screening and re-
ferral of TB suspects, would have contributed to en-
hanced case fi  nding.24 
Second, there is a progressive and highly signifi  -
cant declining trend in TB case notifi  cation  from 
2005 onwards associated with ART scale-up and in-
creased access to ART services at peripheral health 
facilities. Although we cannot know with certainty 
whether or not the observed reduction is linked to 
the ART roll-out, the association between the two is 
suggestive and intuitive. In a high HIV prevalence 
country such as Malawi, high TB incidence in the 
HIV-positive population is likely to be a very impor-
tant contributor to community TB prevalence and 
transmission.7 A reduction in TB risk conferred by 
the ‘ART protective effect’ in this highly susceptible 
subgroup9–13 should therefore reduce TB incidence, 
and subsequently case notifi  cation, at the population 
level. However, trends in case notifi  cation in a given 
setting could be confounded by variables such as high 
mortality prior to TB diagnosis, changes in the effi  -
ciency of TB case detection, the improving socio-
economic status of the population or isoniazid pre-
ventive treatment (IPT) for HIV-positive individuals.25 
However, we do not believe that any of these factors 
would have contributed to the declining trends ob-
served from 2005 onwards in our setting.
HIV care and ART scale-up were achieved and sus-
tained by decentralising these services15,16 and, since 
2006, increasing numbers of health facilities have also 
benefi  ted from an increase in decentralised labora-
tory capability for diagnosing TB. By the end of 2009, 
sputum samples could be examined in seven micros-
copy sites, and an additional eight sites were able to 
perform full preparation (smearing and fi  xation) of 
slides for reading.26 Fluorescent microscopy has also 
been introduced at the district level to cope with the 
high caseloads of sputum samples and to increase di-
agnostic effi  ciency. In other words, the decreasing trend 
in TB case notifi  cations happened despite these efforts 
to enhance TB detection. Furthermore, there has been 
no implementation of IPT in the district, and we do 
not believe that there have been signifi  cant improve-
ments in social conditions such as employment oppor-
tunities or the earning capacity of the population. The 
prices of petrol, diesel and paraffi  n have generally 
shown an upward trend over the study period, with a 
consequent increase in consumer prices.27 The situa-
tion from 2005 onwards is therefore likely to represent 
the overall impact of ART on TB case notifi  cation. 
The strengths of this study are that TB case notifi  -
cation data for an entire district of more than half a 
million inhabitants were included and that the diag-
nosis and reporting systems for TB notifi  cation and 
ART scale-up are standardised and supervised. The 
fi  ndings are thus likely to refl  ect the reality on the 
ground. The main limitation of the study is that it is 
based on simple observational data with the usual re-
lated shortcomings, and we are thus unable to dem-
onstrate a cause-effect relationship. We therefore de-
liberately concentrated on general ‘trend analysis’ of 
case notifi  cation, which is considered a proxy indica-
tor of community TB incidence and prevalence. 
Whatever the exact reasons for the decline, a re-
versal in the trend of TB case notifi  cation associated 
with high ART coverage is very encouraging, as it 
brings some optimism towards achieving the United 
Nations Millennium Development Goal (MDG) tar-
gets,28 where TB control is crucial.29 In addition, it 
reduces the TB caseload burden in an overburdened 
health system facing severe shortages of human re-
sources for health. The benefi  cial effect on TB case 
notifi  cation seen in this context is likely to be accen-
tuated with recent WHO guidelines recommending 
starting ART at higher CD4 counts compared with 
Table 3  Projected estimate of averted new and recurrent TB cases linked to ART, Thyolo District, Malawi, 2002–2009
Year
Total population 
Thyolo District 
n
Total 
registered 
new TB cases
n
Projected number 
of TB cases*
n (95%CI) 
Averted new 
TB cases 
due to ART†
n (95%CI)
Total 
registered 
recurrent 
TB cases
n (95%CI)
Projected 
number of 
recurrent 
TB cases‡
n (95%CI)
Averted 
recurrent 
TB cases§
n (95%CI)
2002 507 426 1120 — —   37 
2003 523 162 1061 — —   82 
2004 539 610 1365 — —   98
2005 556 700 1445 — — 113 —
2006 574  384 1470 1488  (1412–1568)   18  (−58–80) 116 —
2007 592 630 1348 1535 (1458–1618)   187 (110–270) 104 119 (101–142) 15 (−3–38)
2008 611 424 1171 1584 (1504–1669)   413 (333–498)   88 122 (104–147) 34 (16–59)
2009 630 756 1090 1636 (1552–1722)   546 (462–632)   97 126 (107–151) 29 (10–54)
 Total 1163  (847–1480) 78  (23–151)
* Projected number of new TB cases assuming a TB case notiﬁ  cation rate of 259 (246–273)/100 000, observed at a peak level in 2005. 
† Projected number of new TB cases minus the total number of registered new TB cases.
‡ Projected number of recurrent TB cases assuming a recurrent TB case notiﬁ  cation rate of 20 (17–24)/100 000, observed at a peak level in 2005/2006. 
§ Projected number of recurrent TB cases minus the total number of recurrent TB cases.
TB = tuberculosis; ART = antiretroviral treatment; CI = conﬁ  dence interval.Declining   TB   case   rates   with   ART  937
during the period of this study.30 There is now a need 
to further increase impetus in this direction through 
the implementation of the ‘3 Is’, i.e., intensifi  ed case 
fi  nding, improved TB infection control and IPT.31 Fi-
nally, this study provides important and encouraging 
evidence for donors on the population impact of ART 
coverage and advocates for continued involvement in 
ART and TB programmes in similar settings. On the 
other hand, a retreat from investment in such pro-
grammes could be disastrous to sustaining gains such 
as those described in this article. 
In a rural district of Malawi that has achieved high 
ART coverage, there is very encouraging evidence of 
a signifi  cant decline in TB case notifi  cation rates for 
both new and recurrent TB at the population level. 
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OBJECTIFS :  Faire un rapport sur les tendances des taux 
de déclaration des nouveaux cas ou de cas récurrents de 
tuberculose (TB) en relation avec l’extension du traite-
ment antirétroviral (ART) dans un district rural du Ma-
lawi qui s’est lancé dans un accroissement à large échelle 
du ART.
MÉTHODES :  Etude  descriptive  de  vérifi  cation des don-
nées sur les déclarations des cas de TB et sur l’enrôlement 
dans l’ART pendant la période 2002–2009.
RÉSULTATS :    On a enregistré 10  070 nouveaux cas de 
TB et 755 cas de reprise de TB. L’extension de l’ART a 
commencé en 2003 et la couverture a été estimée à 54% 
des sujets nécessitant l’ART en 2006 et à 80% en 2007, 
et s’est maintenue par la suite. Pour les nouveaux cas de 
TB, un accroissement initial des déclarations de cas au 
cours des premières années faisant suite à l’ART (2002–
2005) a été suivi par une diminution hautement signifi  -
cative et persistante de 259 à 173 cas pour 100 000 ha-
bitants (pour les tendances linéaires χ2 = 261, P < 0,001 ; 
réduction cumulative pour la période 2005–2009 = 
33% ; IC95% 27–39). Pour les cas de reprise de TB, 
l’accroissement initial a été suivi par une chute signifi  ca-
tive de 20 à 15 cas/100 000 (pour les tendances linéaires 
χ2 = 8,3 ; P = 0,004), ce qui constitue une réduction cu-
mulative de 25% (IC95% 9–49) des taux de cas pour la 
période 2006–2009. Entre 2005 et 2009, l’extension de 
l’ART a évité un nombre estimé de 1164 nouveaux cas 
de TB (IC95% 847–1480) et de 78 cas de reprise de TB 
(IC95% 23–151).
CONCLUSIONS :  Une large mise en œuvre de l’ART est 
en association avec une tendance décroissante très en-
courageante et signifi  cative des déclarations des nouveaux 
cas ou des reprises de TB au niveau de la population.
OBJETIVOS: Notifi  car las tendencias en materia de noti-
fi  cación de los casos nuevos y las recidivas de tuberculo-
sis (TB) en un distrito rural de Malawi, donde se em-
prendió un programa de ampliación a gran escala del 
tratamiento antirretrovírico (ART). 
MÉTODOS: Fue este un estudio descriptivo. Análisis de 
los datos de notifi  cación de casos de TB y de inscripción 
en el ART entre el 2002 y el 2009. 
RESULTADOS: Se observaron 10  070 casos nuevos de 
TB y 755 recidivas. La ampliación de escala del ART 
comenzó en el 2003 y hacia el 2007 se calculó que su 
cobertura alcanzaba el 80% y esta cifra se mantuvo es-
table en los años siguientes. Con respecto a los casos 
nuevos de TB, un incremento inicial en las notifi  cacio-
nes de casos durante los primeros años de la instaura-
ción del ART (del 2002 al 2005) se continuó con una 
disminución signifi  cativa y constante desde 259 hasta 
173 casos por 100  000 habitantes (χ2 de las tendencias 
261; P < 0,001, disminución acumulada de 33% entre 
el 2005 y el 2009; IC95% 27–39). En relación con los 
casos de recidiva de TB, un aumento inicial se continuó 
con una reducción drástica de 20 a 15 casos/100 000 (χ2 
de la tendencia lineal = 8,3; P = 0,004), con una reduc-
ción acumulada de 25% entre el 2006 y el 2009 (IC95% 
9–49). Se calculó que el ART evitó 1164 casos nuevos de 
TB (IC95% 847–1480) y 78 casos de recidiva (IC95% 
23–151) entre el 2005 y el 2009. 
CONCLUSIÓN: Una alta cobertura del ART se asocia 
con una disminución considerablemente de las tenden-
cias de notifi  cación de casos nuevos de TB y de recidiva 
a escala de la población general.
RÉSUMÉ
RESUMEN